Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2017, Article ID 5164292, 14 pages
https://doi.org/10.1155/2017/5164292
Review Article

Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes

1Agrarian School of Viseu (ESAV), Polytechnic Institute of Viseu (IPV), 3500-606 Viseu, Portugal
2Centre for the Study of Education, Technologies and Health (CI&DETS), Polytechnic Institute of Viseu (IPV), 3500-606 Viseu, Portugal
3Institute of Pharmacology and Experimental Therapeutics and Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal
4CNC.IBILI Research Consortium, University of Coimbra, 3004-504 Coimbra, Portugal

Correspondence should be addressed to Rosa Fernandes; tp.cu.demf@sednanrefcr and Flávio Reis; tp.cu.demf@sierf

Received 21 May 2017; Accepted 12 July 2017; Published 27 August 2017

Academic Editor: Kim Connelly

Copyright © 2017 Cristina Mega et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Virally, J. F. Blicklé, J. Girard, S. Halimi, D. Simon, and P. J. Guillausseau, “Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives,” Diabetic Medicine, vol. 33, pp. 231–244, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. S. E. Kahn, “The importance of the β-cell in the pathogenesis of type 2 diabetes mellitus,” American Journal of Medicine, vol. 108, pp. 2S–8S, 2000. View at Google Scholar
  3. P. Marchetti, R. Lupi, S. D. Guerra, M. Bugliani, L. Marselli, and U. Boggi, “The β-cell in human type 2 diabetes,” Advances in Experimental Medicine and Biology, vol. 654, pp. 501–514, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. E. Cerf, “Beta cell dysfunction and insulin resistance,” Frontiers in Endocrinology, vol. 4, p. 37, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Yagihashi, W. Inaba, and H. Mizukami, “Dynamic pathology of islet endocrine cells in type 2 diabetes: b-cell growth, death, regeneration and their clinical implications,” Journal of Diabetes Investigation, vol. 7, pp. 155–165, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. R. A. D. Fronzo, “From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus (banting lecture),” Diabetes, vol. 58, pp. 773–795, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. D. J. Drucker, “The biology of incretin hormones,” Cell Metabolism, vol. 3, no. 3, pp. 153–165, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Marques, C. Mega, A. Gonçalves et al., “Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals,” Mediators of Inflammation, vol. 2014, Article ID 538737, 15 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. M. K. Piya, P. G. McTernan, and S. Kumar, “Adipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxin,” Journal of Endocrinology, vol. 216, pp. T1–T15, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Guo, “Insulin signaling, resistance, and metabolic syndrome: insights from mouse models into disease mechanisms,” Journal of Endocrinology, vol. 220, pp. T1–T23, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. U. J. Jung and M.-S. Choi, “Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease,” International Journal of Molecular Sciences, vol. 15, no. 4, pp. 6184–6223, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. S. L. Lay, G. Simard, M. C. Martinez, and R. Andriantsitohaina, “Oxidative stress and metabolic pathologies: from an adipocentric point of view,” Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 908539, 18 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Chen, R. Chen, H. Wang, and F. Liang, “Mechanisms linking inflammation to insulin resistance,” International Journal of Endocrinology, vol. 2015, Article ID 508409, 9 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Tangvarasittichai, “Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus,” World Journal of Diabetes, vol. 6, no. 3, pp. 456–480, 2015. View at Publisher · View at Google Scholar
  15. K. N. Keane, V. F. Cruzat, R. Carlessi, P. I. H. de Bittencourt, and P. Newsholme, “Molecular events linking oxidative stress and inflammation to insulin resistance and β-cell dysfunction,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 181643, 15 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. E. J. Bae, “DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control,” Archives of Pharmacal Research, vol. 39, no. 8, pp. 1114–1128, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. L. A. Filla and J. L. Edwards, “Metabolomics in diabetic complications,” Molecular BioSystems, vol. 12, pp. 1090–1105, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Chawla, R. Chawla, and S. Jaggi, “Microvasular and macrovascular complications in diabetes mellitus: distinct or continuum?” Indian Journal of Endocrinology and Metabolism, vol. 20, no. 4, pp. 546–551, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Mima, “Incretin-based therapy for prevention of diabetic vascular complications,” Journal of Diabetes Research, vol. 2016, Article ID 1379274, 12 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. T. S. Kern, “Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy,” Journal of Diabetes Research, vol. 2007, Article ID 95103, 14 pages, 2007. View at Publisher · View at Google Scholar
  21. J. F. Navarro-González and C. Mora-Fernández, “The role of inflammatory cytokines in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 19, pp. 433–442, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. A. M. Vincent, B. C. Callaghan, A. L. Smith, and E. L. Feldman, “Diabetic neuropathy: cellular mechanisms as therapeutic targets,” Nature Reviews Neurology, vol. 7, pp. 573–583, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Narres, H. Claessen, S. Droste et al., “The incidence of end-stage renal disease in the diabetic (compared to the non-diabetic) population: a systematic review,” PLoS One, vol. 11, no. 1, article e0147329, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. J. A. J. G. Van den Brand, “Diabetes mellitus as a cause of end-stage renal disease in Europe: signs of improvement,” Clinical Kidney Journal, vol. 9, no. 3, pp. 454–456, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. American Diabetes Association, “Standards of medical care in diabetes—2017,” Diabetes Care, vol. 40, Supplement 1, 2017. View at Google Scholar
  26. M. Y. Donath, D. M. Schumann, M. Faulenbach, H. Ellingsgaard, A. Perren, and J. A. Ehses, “Islet inflammation in type 2 diabetes: from metabolic stress to therapy,” Diabetes Care, vol. 31, no. 2, pp. S161–S164, 2008. View at Publisher · View at Google Scholar
  27. W. J. Rejeski, E. H. Ip, A. G. Bertoni et al., “Lifestyle change and mobility in obese adults with type 2 diabetes,” New England Journal of Medicine, vol. 366, no. 13, pp. 1209–1217, 2012. View at Google Scholar
  28. J. J. Marín-Peñalver, I. Martín-Timón, C. Sevillano-Collantes, and F. J. del Cañizo-Gómez, “Update on the treatment of type 2 diabetes mellitus,” World Journal of Diabetes, vol. 7, no. 17, pp. 354–395, 2016. View at Publisher · View at Google Scholar
  29. R. Khardori, “Type 2 diabetes mellitus medication,” Medscape, May 2017, http://emedicine.medscape.com/article/117853-overview.
  30. R. Godinho, C. Mega, E. Teixeira-de-Lemos et al., “The place of dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapeutics: a “me too” or “the special one” antidiabetic class?” Journal of Diabetes Research, vol. 2015, Article ID 806979, 28 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. “International Diabetes Federation (IDF) 2014,” https://www.idf.org/about-diabetes/what-is-diabetes.
  32. D. M. Nathan, P. McGee, M. W. Steffes, J. M. Lachin, and DCCT/EDIC Research Group, “Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study,” Diabetes, vol. 63, pp. 282–290, 2014. View at Google Scholar
  33. National Institute for Health and Care Excellence (NICE), “Type 2 diabetes in adults: management. NICE guidelines [NG28] 2015,” April 2017, https://www.nice.org.uk/guidance/ng28/chapter/1-recommendations.
  34. American Diabetes Association (ADA), “Strategies for Improving Care,” Diabetes Care, vol. 39, Supplement 1, pp. S6–S12, 2016. View at Google Scholar
  35. S. Ayadurai, H. L. Hattingh, L. B. G. Tee, and S. N. Md Said, “A narrative review of diabetes intervention studies to explore diabetes care opportunities for pharmacists,” Journal of Diabetes Research, vol. 2016, Article ID 5897452, 11 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Rayman, “Glycaemic control, glucose variability and the triangle of diabetes care,” British Journal of Diabetes, vol. 16, Supplement 1, pp. S3–S6, 2016. View at Publisher · View at Google Scholar · View at Scopus
  37. S. E. Kahn, M. E. Cooper, and S. D. Prato, “Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future,” The Lancet, vol. 383, pp. 1068–1083, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. S. E. Inzucchi, R. M. Bergenstal, J. B. Buse et al., “Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD),” Diabetes Care, vol. 35, no. 6, pp. 1364–1379, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Mata-Cases, D. Mauricio, and J. Franch-Nadal, “Clinical characteristics of type 2 diabetic patients on basal insulin therapy with adequate fasting glucose control who do not achieve HbA1c targets,” Journal of Diabetes, vol. 9, no. 1, pp. 34–44, 2017. View at Publisher · View at Google Scholar
  40. D. Russell-Jones and S. Gough, “Recent advances in incretin-based therapies,” Clinical Endocrinology, vol. 77, no. 4, pp. 489–499, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. B. L. Wajchenberg, “β-cell failure in diabetes and preservation by clinical treatment,” Endocrine Reviews, vol. 28, no. 2, pp. 187–218, 2017. View at Google Scholar
  42. W. T. Cefalu, “The physiologic role of incretin hormones: clinical applications,” Journal of the American Osteopathic Association, vol. 110, Supplement 2, no. 3, pp. S8–S14, 2010. View at Google Scholar
  43. M. C. Riddle, “Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations,” Endocrinology and Metabolism Clinics of North America, vol. 34, pp. 77–98, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. A. A. Hasan and B. Hocher, “Role of soluble and membrane-bound dipeptidylpeptidase-4 in diabetic nephropathy,” Journal of Molecular Endocrinology, vol. 59, no. 1, pp. R1–R10, 2017. View at Publisher · View at Google Scholar
  45. J. E. Gerich, “Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications,” Diabetic Medicine, vol. 27, no. 2, pp. 136–142, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. M. A. Nauck, “Update on developments with SGLT2 inhibitors in the management of type 2 diabetes,” Drug Design Development and Therapy, vol. 8, pp. 1335–1380, 2014. View at Google Scholar
  47. H. Noh and G. L. King, “The role of protein kinase C activation in diabetic nephropathy,” Kidney International, vol. 106, pp. S49–S53, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. N. Tanji, G. S. Markowitz, C. Fu et al., “Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease,” Journal of the American Society of Nephrology, vol. 11, no. 9, pp. 1656–1666, 2000. View at Google Scholar
  49. K. Susztak, A. C. Raff, M. Schiffer, and E. P. Böttinger, “Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy,” Diabetes, vol. 55, no. 1, pp. 225–233, 2006. View at Google Scholar
  50. J. M. Forbes, M. T. Coughlan, and M. E. Cooper, “Oxidative stress as a major culprit in kidney disease in diabetes,” Diabetes, vol. 57, no. 6, pp. 1446–1454, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. Z. Cao and M. E. Cooper, “Pathogenesis of diabetic nephropathy,” Journal of Diabetes Investigation, vol. 2, no. 4, pp. 243–247, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. D. K. Singh, P. Winocour, and K. Farrington, “Oxidative stress in early diabetic nephropathy: fueling the fire,” Nature Reviews Endocrinology, vol. 7, no. 3, pp. 176–184, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. X. Chen, Z. Ren, W. Liang et al., “c-Abl mediates angiotensin II-induced apoptosis in podocytes,” Journal of Molecular Histology, vol. 44, no. 5, pp. 597–608, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. V. P. Singh, A. Bali, N. Singh, and A. S. Jaggi, “Advanced glycation end products and diabetic complications,” The Korean Journal of Physiology & Pharmacology, vol. 18, no. 1, pp. 1–14, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Rivero, C. Mora, M. Muros, J. García, H. Herrera, and J. F. Navarro-González, “Pathogenic perspectives for the role of inflammation in diabetic nephropathy,” Clinical Science, vol. 116, no. 6, pp. 479–492, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. P. Gao, F.-F. He, H. Tang et al., “NADPH oxidase-induced NALP3 inflammasome activation is driven by thioredoxin-interacting protein which contributes to podocyte injury in hyperglycemia,” Journal of Diabetes Research, vol. 2015, Article ID 504761, 12 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  57. K. Kanasaki, G. Taduri, and D. Koya, “Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis,” Frontiers in Endocrinology, vol. 4, p. 7, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. M. B. Duran-Salgado and A. F. Rubio-Guerra, “Diabetic nephropathy and inflammation,” World Journal of Diabetes, vol. 5, no. 3, pp. 393–398, 2014. View at Publisher · View at Google Scholar
  59. S. Morano, R. Cipriani, C. Santangelo et al., “Angiotensin blockade and matrix synthesis by glomerular epithelial cells in high glucose: a further experimental insight into the pathophysiology of diabetic nephropathy,” Clinical Therapeutics, vol. 159, no. 3, pp. 151–154, 2008. View at Google Scholar
  60. T. Chawla, D. Sharma, and A. Singh, “Role of the renin angiotensin system in diabetic nephropathy,” World Journal of Diabetes, vol. 1, no. 5, pp. 141–145, 2010. View at Publisher · View at Google Scholar
  61. M. H. A. Muskiet, M. M. Smits, L. M. Morsink, and M. Diamant, “The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?” Nature Reviews Nephrology, vol. 10, pp. 88–103, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. S. M. Marshall, “Recent advances in diabetic nephropathy,” Postgraduate Medical Journal, vol. 80, pp. 624–633, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. E. Bortoloso, D. D. Prete, M. Dalla Vestra et al., “Quantitative and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetes,” European Journal of Endocrinology, vol. 150, pp. 799–807, 2004. View at Google Scholar
  64. H. J. Baelde, M. Eikmans, D. W. Lappin et al., “Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss,” Kidney International, vol. 71, pp. 637–645, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. J. J. Li, S. J. Kwak, D. S. Jung et al., “Podocyte biology in diabetic nephropathy,” Kidney International, vol. 106, pp. S36–S42, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. J. S. Lin and K. Susztak, “Podocytes: the weakest link in diabetic kidney disease?” Current Diabetes Reports, vol. 16, no. 5, p. 45, 2016. View at Publisher · View at Google Scholar · View at Scopus
  67. J. R. Sowers, A. Whaley-Connell, and M. R. Hayden, “The role of overweight and obesity in the cardiorenal syndrome,” Cardiorenal Medicine, vol. 1, pp. 5–12, 2011. View at Google Scholar
  68. P. Schlatter, C. Beglinger, J. Drewe, and H. Gutmann, “Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells,” Regulatory Peptides, vol. 141, pp. 120–128, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Aroor, S. McKarns, R. Nistala et al., “DPP-4 inhibitors as therapeutic modulators of immune cell function and associated cardiovascular and renal insulin resistance in obesity and diabetes,” Cardiorenal Medicine, vol. 3, no. 1, pp. 48–56, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Yu, C. Moreno, K. M. Hoagland et al., “Antihypertensive effect of glucagonlike peptide 1 in Dahl salt-sensitive rats,” Journal of Hypertension, vol. 21, pp. 1125–1135, 2003. View at Publisher · View at Google Scholar
  71. E. P. Jensen, S. S. Poulsen, H. Kissow et al., “Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow,” American Journal of Physiology - Renal Physiology, vol. 308, no. 8, pp. F867–F877, 2015. View at Publisher · View at Google Scholar · View at Scopus
  72. T. A. Salles, L. dos Santos, V. G. Barauna, and A. C. C. Girardi, “Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failure,” International Journal of Molecular Sciences, vol. 16, no. 2, pp. 4226–4249, 2015. View at Publisher · View at Google Scholar · View at Scopus
  73. E. E. Mulvihill and D. J. Drucker, “Metabolic implications of DPP-4 inhibition,” Endocrine Reviews, vol. 35, no. 6, pp. 992–1019, 2014. View at Google Scholar
  74. K. V. Websky, C. Reichetzedera, and B. Hochera, “Physiology and pathophysiology of incretins in the kidney,” Current Opinion in Nephrology and Hypertension, vol. 23, no. 1, pp. 54–60, 2014. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Shi, D. Koya, and K. Kanasaki, “Dipeptidyl peptidase-4 and kidney fibrosis in diabetes,” Fibrogenesis & Tissue Repair, vol. 9, p. 1, 2016. View at Publisher · View at Google Scholar · View at Scopus
  76. G. P. Fadini, E. Boscaro, M. Albiero et al., “The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes mellitus. Possible role of stromal derived factor-1α,” Diabetes Care, vol. 33, pp. 1607–1609, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. G. L. Plosker, “Sitagliptin: a review of its use in patients with type 2 diabetes mellitus,” Drugs, vol. 74, pp. 223–242, 2014. View at Publisher · View at Google Scholar · View at Scopus
  78. G. A. Herman, C. Stevens, K. Van Dyck et al., “Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses,” Journal of Clinical Pharmacology and Therapeutics, vol. 78, no. 6, pp. 675–688, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. A. J. Bergman, J. Cote, B. Yi et al., “Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor,” Diabetes Care, vol. 30, no. 7, pp. 1862–1864, 2007. View at Google Scholar
  80. E. M. Migoya, C. H. Stevens, A. J. Bergman et al., “Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin,” Canadian Journal of Clinical Pharmacology, vol. 16, no. 1, pp. 165–170, 2009. View at Google Scholar
  81. J. C. Arjona Ferreira, M. Marre, N. Barzilai et al., “Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency,” Diabetes Care, vol. 36, no. 5, pp. 1067–1073, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. J. J. Neumiller and I. B. Hirsch, “Management of hyperglycemia in diabetic kidney disease,” Diabetes Spectrum, vol. 28, no. 3, pp. 214–219, 2015. View at Publisher · View at Google Scholar · View at Scopus
  83. C. C. R. Betônico, S. M. O. Titan, M. L. C. Correa-Giannella, M. Nery, and M. Queiroz, “Management of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic control,” Clinics, vol. 71, no. 1, pp. 47–53, 2016. View at Publisher · View at Google Scholar · View at Scopus
  84. D. Kim, L. Wang, M. Beconi et al., “2(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1, 2, 4]triazolo[4,3-a]pyrazin-7(8H)- yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes,” Journal of Medicinal Chemistry, vol. 48, no. 1, pp. 141–151, 2005. View at Google Scholar
  85. S. E. Inzucchi and D. K. McGuire, “New drugs for the treatment of diabetes: part II. Incretin-based therapy and beyond,” Circulation, vol. 117, no. 4, pp. 574–584, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. B. Ahrén, “Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications,” Diabetes Care, vol. 30, no. 6, pp. 1344–1350, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. R. K. Campbell, “Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus,” Annals of Pharmacotherapy, vol. 41, no. 1, pp. 51–60, 2007. View at Google Scholar
  88. J. Rosenstock and B. Zinman, “Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus,” Current Opinion in Endocrinology, Diabetes, and Obesity, vol. 14, no. 2, pp. 98–107, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. L. L. Baggio and D. J. Drucker, “Biology of incretins: GLP-1 and GIP,” Gastroenterology, vol. 132, no. 6, pp. 2131–2157, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. J. F. Gautier, S. P. Choukem, and J. Girard, “Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes,” Diabetes & Metabolism, vol. 34, Supplement 2, pp. S65–S72, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. C. F. Deacon, P. Danielsen, L. Klarskov, M. Olesen, and J. J. Holst, “Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs,” Diabetes, vol. 50, no. 7, pp. 1588–1597, 2001. View at Google Scholar
  92. G. A. Herman, A. Bergman, F. Liu et al., “Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects,” Journal of Clinical Pharmacology, vol. 46, no. 8, pp. 876–886, 2006. View at Publisher · View at Google Scholar · View at Scopus
  93. B. Ahrén, E. Simonsson, H. Larsson et al., “Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes,” Diabetes Care, vol. 25, no. 5, pp. 869–875, 2002. View at Google Scholar
  94. B. Ahrén, “Insulin plus incretin: a glucose-lowering strategy for type 2-diabetes,” World Journal of Diabetes, vol. 5, no. 1, pp. 40–51, 2014. View at Publisher · View at Google Scholar
  95. A. J. Scheen, “Pharmacokinetics of dipeptidylpeptidase-4 inhibitors,” Diabetes Obesity and Metabolism, vol. 12, no. 8, pp. 648–658, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. S. S. Engel, E. Round, G. T. Golm, K. D. Kaufman, and B. J. Goldstein, “Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies,” Diabetes Therapy, vol. 4, no. 1, pp. 119–145, 2013. View at Publisher · View at Google Scholar · View at Scopus
  97. K. Garg, C. D. Tripathi, and S. Kumar, “Clinical review of sitagliptin: a DPP-4 inhibitor,” Journal of the Association of Physicians of India, vol. 61, pp. 57–61, 2013. View at Google Scholar
  98. K. Esposito, P. Chiodini, M. I. Maiorino, G. Bellastella, A. Capuano, and D. Giugliano, “Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials,” BMJ Open, vol. 4, article e005442, 2014. View at Publisher · View at Google Scholar · View at Scopus
  99. J. Mu, J. Woods, and Y. P. Zhou, “Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes,” Diabetes, vol. 55, no. 6, pp. 1695–1704, 2006. View at Publisher · View at Google Scholar · View at Scopus
  100. J. Mu, A. Petrov, G. J. Eiermann et al., “Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes,” European Journal of Pharmacology, vol. 623, pp. 148–154, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. L. Ferreira, E. Teixeira-de-Lemos, F. Pinto et al., “Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat),” Mediators of Inflammation, vol. 2010, Article ID 592760, 11 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. M. Ji, L. Xia, J. Cao, and D. Zou, “Sitagliptin/metformin versus insulin glargine combined with metformin in obese subjects with newly diagnosed type 2 diabetes,” Medicine, vol. 95, no. 11, article e2961, 2016. View at Publisher · View at Google Scholar · View at Scopus
  103. Y. Kondo, N. Harada, A. Hamasaki et al., “Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial,” Diabetology & Metabolic Syndrome, vol. 8, no. 15, 2016. View at Publisher · View at Google Scholar · View at Scopus
  104. X. Ren, G. Liu, Y. Wang et al., “Influence of dipeptidyl peptidase-IV inhibitor sitagliptin on extracellular signal-regulated kinases 1/2 signaling in rats with diabetic nephropathy,” Pharmacology, vol. 100, pp. 1–13, 2017. View at Publisher · View at Google Scholar
  105. B. Gallwitz, “Extra-pancreatic effects of incretin-based therapies,” Endocrine, vol. 47, no. 2, pp. 360–371, 2014. View at Publisher · View at Google Scholar · View at Scopus
  106. E. J. Verspohl, “Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like-peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors,” Pharmacology & Therapeutics, vol. 124, pp. 113–138, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. R. E. Van Genugten, D. H. van Raalte, and M. Diamant, “Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence,” Diabetes Obesity and Metabolism, vol. 14, pp. 101–111, 2012. View at Publisher · View at Google Scholar · View at Scopus
  108. Y. Zeng, C. Li, M. Guan et al., “The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms,” Cardiovascular Diabetology, vol. 13, no. 32, 2014. View at Publisher · View at Google Scholar · View at Scopus
  109. A. V. Matveyenko, S. Dry, H. I. Cox et al., “Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin,” Diabetes, vol. 58, no. 7, pp. 1604–1615, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. Y. S. Liu, Z. W. Huang, L. Wang et al., “Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats,” Journal of Pharmacological Sciences, vol. 127, no. 3, pp. 260–274, 2015. View at Publisher · View at Google Scholar · View at Scopus
  111. L. M. McCormick, A. C. Kydd, P. A. Read et al., “Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease,” Circulation: Cardiovascular Imaging, vol. 7, no. 2, pp. 274–281, 2014. View at Publisher · View at Google Scholar · View at Scopus
  112. N. Apaijai, H. Pintana, S. C. Chattipakorn, and N. Chattipakorn, “Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin resistant rats,” British Journal of Pharmacology, vol. 169, no. 5, pp. 1048–1057, 2013. View at Google Scholar
  113. B. Picatoste, E. Ramírez, A. Caro-Vadillo et al., “Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms,” PLoS One, vol. 8, no. 10, article e78330, 2013. View at Publisher · View at Google Scholar · View at Scopus
  114. P. A. Read, F. Z. Khan, P. M. Heck, S. P. Hoole, and D. P. Dutka, “DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease,” Circulation. Cardiovascular Imaging, vol. 3, no. 2, pp. 195–201, 2010. View at Publisher · View at Google Scholar · View at Scopus
  115. M. T. Kelleni, E. F. Amin, and A. M. Abdelrahman, “Effect of metformin and sitagliptin on doxorubicin-induced cardiotoxicity in rats: impact of oxidative stress, inflammation, and apoptosis,” Journal of Toxicology, vol. 2015, Article ID 424813, 8 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  116. T. Mita, N. Katakami, T. Shiraiwa et al., “Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: the sitagliptin preventive study of intima-media thickness evaluation (spike): a randomized controlled trial,” Diabetes Care, vol. 39, no. 3, pp. 455–464, 2016. View at Publisher · View at Google Scholar · View at Scopus
  117. R. E. Amori, J. Lau, and A. G. Pittas, “Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis,” Journal of the American Medical Association, vol. 298, no. 2, pp. 194–206, 2007. View at Publisher · View at Google Scholar · View at Scopus
  118. M. Fan, Y. Li, and S. Zhang, “Effects of sitagliptin on lipid profiles in patients with type 2 diabetes mellitus: a meta-analysis of randomized clinical trials,” Medicine, vol. 95, no. 2, pp. 1–9, 2016. View at Publisher · View at Google Scholar · View at Scopus
  119. P. C. M. Van Poppel, M. G. Netea, P. Smits, and C. Tack, “Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes,” Diabetes Care, vol. 34, no. 9, pp. 2072–2077, 2011. View at Publisher · View at Google Scholar · View at Scopus
  120. J. S. Yoon and H. W. Lee, “Understanding the cardiovascular effects of incretin,” Diabetes & Metabolism Journal, vol. 35, no. 5, pp. 437–443, 2011. View at Publisher · View at Google Scholar · View at Scopus
  121. C. Mega, H. Vala, P. Rodrigues-Santos et al., “Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker diabetic fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties,” Diabetology & Metabolic Syndrome, vol. 6, no. 1, p. 42, 2014. View at Publisher · View at Google Scholar · View at Scopus
  122. A. Gonçalves, E. Leal, A. Paiva et al., “Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model,” Diabetes, Obesity and Metabolism, vol. 14, no. 5, pp. 454–463, 2012. View at Publisher · View at Google Scholar · View at Scopus
  123. A. Gonçalves, C. Marques, E. Leal et al., “Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1842, no. 9, pp. 1454–1463, 2014. View at Publisher · View at Google Scholar · View at Scopus
  124. C. Mega, E. T. de Lemos, H. Vala et al., “Diabetic nephropathy amelioration by a low dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat),” Experimental Diabetes Research, vol. 2011, Article ID 162092, 12 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  125. A. Maida, T. Hansotia, C. Longuet, T. Seino, and D. J. Drucker, “Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for β cell survival in mice,” Gastroenterology, vol. 137, pp. 2146–2157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  126. J. A. Yeom, E. S. Kim, H. S. Park et al., “Both sitagliptin analogue & pioglitazone preserve the β-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice,” BMB Reports, vol. 44, no. 11, pp. 713–718, 2011. View at Google Scholar
  127. Y. Takeda, Y. Fujita, and J. Honjo, “Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice,” Diabetologia, vol. 55, no. 2, pp. 404–412, 2012. View at Publisher · View at Google Scholar · View at Scopus
  128. S. Karabulut, Z. M. Coskunb, and S. Bolkent, “Immunohistochemical, apoptotic and biochemical changes by dipeptidyl peptidase-4 inhibitor-sitagliptin in type-2 diabetic rats,” Pharmacological Reports, vol. 67, no. 5, pp. 846–853, 2015. View at Publisher · View at Google Scholar · View at Scopus
  129. J. Shirakawa, T. Okuyama, M. Kyohara et al., “DPP-4 inhibition improves early mortality, β cell function, and adipose tissue inflammation in db/db mice fed a diet containing sucrose and linoleic acid,” Diabetology & Metabolic Syndrome, vol. 8, no. 16, 2016. View at Publisher · View at Google Scholar · View at Scopus
  130. A. D. Dobrian, Q. Ma, J. W. Lindsay et al., “Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice,” American Journal of Physiology: Endocrinology and Metabolism, vol. 300, no. 2, pp. E410–E421, 2011. View at Publisher · View at Google Scholar · View at Scopus
  131. N. Satoh-Asahara, Y. Sasaki, H. Wada et al., “A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients,” Metabolism, vol. 62, no. 3, pp. 347–351, 2013. View at Publisher · View at Google Scholar · View at Scopus
  132. G. Derosa, A. Carbone, A. D’Angelo et al., “Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin,” Internal Medicine, vol. 52, no. 19, pp. 2179–2187, 2013. View at Google Scholar
  133. F. Beguinot, “Tribbles homologue 3 (TRIB3) and the insulin-resistance genes in type 2 diabetes,” Diabetologia, vol. 53, pp. 1831–1834, 2010. View at Publisher · View at Google Scholar · View at Scopus
  134. S. Prudente, D. Scarpelli, M. Chandalia et al., “The trib3 Q84R polymorphism and risk of early-onset type 2 diabetes,” Journal of Clinical Endocrinology & Metabolism, vol. 94, no. 1, pp. 190–196, 2009. View at Publisher · View at Google Scholar · View at Scopus
  135. J. Shirakawa, H. Fujii, K. Ohnuma et al., “Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice,” Diabetes, vol. 60, pp. 1246–1257, 2011. View at Publisher · View at Google Scholar · View at Scopus
  136. S. Oyadomari, H. P. Harding, Y. Zhang, M. Oyadomari, and D. Ron, “Dephosphorylation of translation initiation factor 2α enhances glucose tolerance and attenuates hepatosteatosis in mice,” Cell Metabolism, vol. 7, pp. 520–532, 2008. View at Publisher · View at Google Scholar · View at Scopus
  137. V. Aviv, I. Meivar-Levy, I. H. Rachmut, T. Rubinek, E. Mor, and S. Ferber, “Exendin-4 promotes liver cell proliferation and enhances PDX-1-induced liver to pancreas transdifferentiation,” The Journal of Biological Chemistry, vol. 284, no. 48, pp. 33509–33520, 2009. View at Publisher · View at Google Scholar · View at Scopus
  138. L. Gaetaniello, M. Fiore, S. de Filippo, N. Pozzi, S. Tamasi, and C. Pignata, “Occupancy of dipeptidyl peptidase IV activates an associated tyrosine kinase and triggers an apoptotic signal in human hepatocarcinoma cells,” Hepatology, vol. 27, pp. 934–942, 1998. View at Google Scholar
  139. M. E. Kelany, T. M. Hakami, A. H. Omar, and M. A. Abdallah, “Combination of sitagliptin and insulin against type 2 diabetes mellitus with neuropathy in rats: neuroprotection and role of oxidative and inflammation stress,” Pharmacology, vol. 98, pp. 242–250, 2016. View at Publisher · View at Google Scholar · View at Scopus
  140. B. F. Schrijvers, A. Flyvbjerg, R. G. Tilton, N. H. Lameire, and A. S. D. Vriese, “A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat,” Nephrology Dialysis Transplantation, vol. 21, no. 2, pp. 324–329, 2006. View at Publisher · View at Google Scholar · View at Scopus
  141. L. Liu, J. Liu, W. T. Wong et al., “Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism,” Hypertension, vol. 60, pp. 833–841, 2012. View at Publisher · View at Google Scholar · View at Scopus
  142. S. Kröller-Schön, M. Knorr, M. Hausding et al., “Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition,” Cardiovascular Research, vol. 96, pp. 140–149, 2012. View at Publisher · View at Google Scholar · View at Scopus
  143. I. Kawasaki, Y. Hiura, A. Tamai et al., “Sitagliptin reduces the urine albumin-to-creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rate,” Journal of Diabetes, vol. 7, no. 1, pp. 41–46, 2015. View at Publisher · View at Google Scholar · View at Scopus
  144. L. M. Russo, R. M. Sandoval, S. B. Campos, B. A. Molitoris, W. D. Comper, and D. Brown, “Impaired tubular uptake explains albuminuria in early diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 20, no. 3, pp. 489–494, 2009. View at Publisher · View at Google Scholar · View at Scopus
  145. G. B. Peres and Y. M. Michelacci, “The role of proximal tubular cells in the early stages of diabetic nephropathy,” Journal of Diabetes & Metabolism, vol. 6, p. 551, 2015. View at Google Scholar
  146. A. C. Girardi, B. C. Degray, T. Nagy, D. Biemesderfer, and P. S. Aronson, “Association of Na+-H+ exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule,” The Journal of Biological Chemistry, vol. 276, no. 49, pp. 46671–46677, 2001. View at Publisher · View at Google Scholar · View at Scopus
  147. D. F. Arruda-Junior, F. L. Martins, R. Dariolli et al., “Dipeptidyl peptidase IV inhibition exerts renoprotective effects in rats with established heart failure,” Frontiers in Physiology, vol. 7, p. 293, 2016. View at Publisher · View at Google Scholar · View at Scopus
  148. R. Nistala, J. Habibi, G. Lastra et al., “Prevention of obesity-induced renal injury in male mice by DPP4 inhibition,” Endocrinology, vol. 155, no. 6, pp. 2266–2276, 2014. View at Publisher · View at Google Scholar · View at Scopus
  149. R. Nistala, J. Habibi, A. Aroor et al., “DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat,” Obesity, vol. 22, no. 10, pp. 2172–2179, 2014. View at Publisher · View at Google Scholar · View at Scopus
  150. W. J. Liu, S. H. Xie, Y. N. Liu et al., “Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 340, pp. 248–255, 2012. View at Publisher · View at Google Scholar · View at Scopus
  151. A. Aroor, M. Zuberek, C. Duta et al., “Angiotensin II stimulation of DPP4 activity regulates megalin in the proximal tubules,” International Journal of Molecular Sciences, vol. 17, no. 5, 2016. View at Publisher · View at Google Scholar · View at Scopus
  152. B. Hocher, C. Reichetzeder, and M. L. Alter, “Renal and cardiac effects of DPP-4 inhibitors – from preclinical development to clinical research,” Kidney and Blood Pressure Research, vol. 36, pp. 65–84, 2012. View at Publisher · View at Google Scholar · View at Scopus
  153. B. P. Pacheco, R. O. Crajoinas, G. K. Couto et al., “Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats,” Journal of Hypertension, vol. 29, pp. 520–528, 2011. View at Publisher · View at Google Scholar · View at Scopus
  154. S. Saha, Y. Li, and M. B. Anand-Srivastava, “Reduced levels of cyclic AMP contribute to the enhanced oxidative stress in vascular smooth muscle cells from spontaneously hypertensive rats,” Canadian Journal of Physiology and Pharmacology, vol. 86, pp. 190–198, 2008. View at Publisher · View at Google Scholar · View at Scopus
  155. A. Avogaro and G. P. Fadini, “The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications,” Diabetes Care, vol. 37, no. 10, pp. 2884–2894, 2014. View at Publisher · View at Google Scholar · View at Scopus
  156. A. A. Eddy, “Serine proteases, inhibitors and receptors in renal fibrosis,” Thrombosis and Haemostasis, vol. 101, no. 4, pp. 656–664, 2009. View at Google Scholar
  157. G. Tramonti and Y. S. Kanwar, “Tubular biomarkers to assess progression of diabetic nephropathy,” Kidney International, vol. 79, no. 10, pp. 1042–1044, 2011. View at Publisher · View at Google Scholar · View at Scopus
  158. S. Hoshi, Y. Shu, F. Yoshida et al., “Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats,” Laboratory Investigation, vol. 82, no. 1, pp. 25–35, 2002. View at Google Scholar
  159. N. Gassler, M. Elger, B. Kränzlin et al., “Podocyte injury underlies the progression of focal segmental glomerulosclerosis in the fa/fa Zucker rat,” Kidney International, vol. 60, no. 1, pp. 106–116, 2001. View at Publisher · View at Google Scholar · View at Scopus
  160. T. W. Tervaert, A. L. Mooyaart, K. Amann et al., “Pathologic classification of diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 21, no. 4, pp. 556–563, 2010. View at Publisher · View at Google Scholar · View at Scopus
  161. K. White, “Histological appearance of diabetic nephropathy,” Diapedia 7105002828 rev., no. 5, 2014. View at Publisher · View at Google Scholar
  162. U. Panchapakesan and C. Pollock, “The role of dipeptidyl peptidase – 4 inhibitors in diabetic kidney disease,” Frontiers in Immunology, vol. 6, p. 443, 2015. View at Publisher · View at Google Scholar · View at Scopus
  163. H. S. Min, J. E. Kim, M. H. Lee et al., “Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction,” Laboratory Investigation, vol. 94, no. 6, pp. 598–607, 2014. View at Publisher · View at Google Scholar · View at Scopus
  164. S. Shi, S. P. Srivastava, M. Kanasaki et al., “Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition,” Kidney International, vol. 88, no. 3, pp. 479–489, 2015. View at Publisher · View at Google Scholar · View at Scopus
  165. G. Tonolo and S. Cherchi, “Tubulointerstitial disease in diabetic nephropathy,” International Journal of Nephrology and Renovascular Disease, vol. 7, pp. 107–115, 2014. View at Publisher · View at Google Scholar · View at Scopus
  166. P. Vavrinec, R. H. Henning, S. W. Landheer et al., “Vildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in Zucker diabetic fatty rat,” Current Vascular Pharmacology, vol. 12, pp. 836–844, 2014. View at Google Scholar
  167. I. Raz, M. Hanefeld, L. Xu et al., “Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus,” Diabetologia, vol. 49, no. 11, pp. 2564–2571, 2006. View at Google Scholar
  168. V. Gupta and S. Kalra, “Choosing a gliptin,” Indian Journal of Endocrinology and Metabolism, vol. 15, no. 4, pp. 298–308, 2011. View at Publisher · View at Google Scholar
  169. Y. Wang, S. Landheer, W. H. van Gilst et al., “Attenuation of renovascular damage in Zucker diabetic fatty rat by NWT-03, an egg protein hydrolysate with ACE- and DPP-4-inhibitory activity,” PLoS One, vol. 7, no. 10, article e46781, 2012. View at Publisher · View at Google Scholar · View at Scopus
  170. H. Y. Jin, W. J. Liu, J. H. Park, H. S. Baek, and T. S. Park, “Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats,” Archives of Medical Research, vol. 40, pp. 536–544, 2009. View at Publisher · View at Google Scholar · View at Scopus
  171. Y. Ishibashi, S. Yamagishi, T. Matsui et al., “Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level,” Metabolism, vol. 61, pp. 1067–1072, 2012. View at Publisher · View at Google Scholar · View at Scopus
  172. T. Tanaka, Y. Higashijima, T. Wada, and M. Nangaku, “The potential for renoprotection with incretin-based drugs,” Kidney International, vol. 86, pp. 701–711, 2014. View at Publisher · View at Google Scholar · View at Scopus
  173. J. L. Górriz, J. Nieto, J. F. Navarro-González, P. Molina, A. Martínez-Castelao, and L. M. Pallardó, “Nephroprotection by hypoglycemic agents: do we have supporting data?” Journal of Clinical Medicine, vol. 4, no. 10, pp. 1866–1889, 2015. View at Publisher · View at Google Scholar
  174. W. S. Silva Júnior, A. F. Godoy-Matos, and L. G. Kraemer-Aguiar, “Dipeptidyl peptidase 4: a new link between diabetes mellitus and atherosclerosis?” Biomedical Research International, vol. 2015, Article ID 816164, 10 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  175. V. Matheeussen, L. Baerts, G. De Meyer et al., “Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries,” Biological Chemistry, vol. 392, no. 3, pp. 189–198, 2011. View at Publisher · View at Google Scholar · View at Scopus
  176. T. Romacho, S. Vallejo, L. A. Villalobos et al., “Soluble dipeptidyl peptidase-4 induces microvascular endothelial dysfunction through proteinase-activated receptor-2 and thromboxane A2 release,” Journal of Hypertension, vol. 34, no. 5, pp. 869–876, 2016. View at Publisher · View at Google Scholar · View at Scopus
  177. C. G. Yu, N. Zhang, S. S. Yuan et al., “Endothelial progenitor cells in diabetic microvascular complications: friends or foes?” Stem Cells International, vol. 2016, Article ID 1803989, 10 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  178. R. H. Ahmed, H. Z. Huri, Z. Al-Hamodi, S. D. Salem, and S. Muniandy, “Serum levels of soluble CD26/dipeptidyl peptidase-IV in type 2 diabetes mellitus and its association with metabolic syndrome and therapy with antidiabetic agents in Malaysian subjects,” PLoS One, vol. 10, no. 10, article e0140618, 2015. View at Publisher · View at Google Scholar · View at Scopus
  179. D. Röhrborn, N. Wronkowitz, and J. Eckel, “DPP-4 in diabetes,” Frontiers in Immunology, vol. 6, p. 386, 2015. View at Publisher · View at Google Scholar · View at Scopus
  180. J. Donate-Correa, E. Martín-Núñez, M. Muros-de-Fuentes, C. Mora-Fernández, and J. F. Navarro-González, “Inflammatory cytokines in diabetic nephropathy,” Journal of Diabetes Research, vol. 2015, Article ID 948417, 9 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  181. J. F. Navarro and C. Mora, “Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy,” The Scientific World Journal, vol. 6, pp. 908–917, 2006. View at Publisher · View at Google Scholar · View at Scopus
  182. X. Ren, G. Liu, Y. Wang et al., “Influence of dipeptidyl peptidase-iv inhibitor sitagliptin on extracellular signal-regulated kinases 1/2 signaling in rats with diabetic nephropathy,” Pharmacology, vol. 100, no. 1-2, pp. 1–13, 2017. View at Publisher · View at Google Scholar
  183. J. S. Nielsen and K. M. McNagny, “Novel functions of the CD34 family,” Journal of Cell Science, vol. 121, Part 22, pp. 3682–3692, 2008. View at Publisher · View at Google Scholar · View at Scopus
  184. J. H. Li, W. Wang, X. R. Huang et al., “Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway,” The American Journal of Pathology, vol. 164, no. 4, pp. 1389–1397, 2004. View at Publisher · View at Google Scholar
  185. K. B. Gomes, K. F. Rodrigues, and A. P. Fernandes, “The role of transforming growth factor-beta in diabetic nephropathy,” International Journal of Medical Genetics, vol. 2014, Article ID 180270, 6 pages, 2014. View at Publisher · View at Google Scholar
  186. F. Yang, T. Yu, K. Li, X. Jiang, J. Li, and J. Wang, “Sitagliptin reduces transforming growth factor-β1 and platelet derived growth factor-BB in regulation of UAER in type 2 diabetic nephropathy stage III patients,” Biomedical Research, vol. 28, no. 6, pp. 2571–2577, 2017. View at Google Scholar
  187. S. S. Bessa, T. A. Hussein, M. A. Morad, and A. M. Amer, “Urinary platelet-derived growth factor-BB as an early marker of nephropathy in patients with type 2 diabetes: an Egyptian study,” Renal Failure, vol. 34, no. 6, pp. 670–675, 2012. View at Publisher · View at Google Scholar · View at Scopus
  188. Y. Ishibashi, Y. Nishino, T. Matsui, M. Takeuchi, and S. I. Yamagishi, “Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level,” Metabolism, vol. 60, no. 9, pp. 1271–1277, 2011. View at Publisher · View at Google Scholar · View at Scopus
  189. J. Li, M. Guan, C. Li et al., “The dipeptidyl peptidase-4 inhibitor sitagliptin protects against dyslipidemia-related kidney injury in apolipoprotein E knockout mice,” International Journal of Molecular Sciences, vol. 15, pp. 11416–11434, 2014. View at Publisher · View at Google Scholar · View at Scopus
  190. H. S. Lee, “Mechanisms and consequences of hypertriglyceridemia and cellular lipid accumulation in chronic kidney disease and metabolic syndrome,” Histology and Histopathology, vol. 26, no. 12, pp. 1599–1610, 2011. View at Publisher · View at Google Scholar
  191. A. R. Martins and S. Mas, “Lipotoxicity and kidney,” Portuguese Journal of Nephrology & Hypertension, vol. 29, no. 4, pp. 306–315, 2015. View at Google Scholar
  192. S. J. Glastras, H. Chen, R. T. McGrath et al., “Effect of GLP-1 receptor activation on offspring kidney health in a rat model of maternal obesity,” Scientific Reports, vol. 6, article 23525, 2016. View at Publisher · View at Google Scholar · View at Scopus
  193. F. A. Wagener, D. Dekker, J. H. Berden, A. Scharstuhl, and J. van der Vlag, “The role of reactive oxygen species in apoptosis of the diabetic kidney,” Apoptosis, vol. 14, no. 12, pp. 1451–1458, 2009. View at Publisher · View at Google Scholar · View at Scopus
  194. M. D. Sanchez-Niño, A. Benito-Martin, and A. Ortiz, “New paradigms in cell death in human diabetic nephropathy,” Kidney International, vol. 78, no. 8, pp. 737–744, 2010. View at Publisher · View at Google Scholar · View at Scopus
  195. J. Vaghasiya, N. Sheth, Y. Bhalodia, and R. Manek, “Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes,” Regulatory Peptides, vol. 166, no. 1–3, pp. 48–54, 2011. View at Publisher · View at Google Scholar · View at Scopus
  196. H. Hendarto, T. Inoguchi, Y. Maeda et al., “GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A mediated inhibition of renal NAD(P)H oxidases,” Metabolism, vol. 61, no. 10, pp. 1422–1434, 2012. View at Publisher · View at Google Scholar · View at Scopus
  197. R. Kodera, K. Shikata, T. Takasuta et al., “Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its antiinflammatory action in a rat model of type 1 diabetes,” Biochemical and Biophysical Research Communications, vol. 443, no. 3, pp. 828–833, 2014. View at Publisher · View at Google Scholar · View at Scopus
  198. S. Nakashima, T. Matsui, M. Takeuchi, and S. I. Yamagishi, “Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis,” Hormone and Metabolic Research, vol. 46, pp. 717–721, 2014. View at Publisher · View at Google Scholar · View at Scopus
  199. T. Matsui, S. Nakashima, Y. Nishino et al., “Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis,” Laboratory Investigation, vol. 95, no. 5, pp. 525–533, 2015. View at Publisher · View at Google Scholar · View at Scopus